<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01774487</url>
  </required_header>
  <id_info>
    <org_study_id>BCM/TCH-H-31387</org_study_id>
    <nct_id>NCT01774487</nct_id>
  </id_info>
  <brief_title>Pentoxifylline Therapy in Biliary Atresia</brief_title>
  <official_title>A Phase II Trial of Pentoxifylline in Newly-Diagnosed Biliary Atresia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Baylor College of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Texas Children's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Baylor College of Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether pentoxifylline reduces liver damage in
      infants with biliary atresia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Biliary atresia (BA) is a devastating liver disease of infancy of unknown etiology,
      characterized by bile duct obstruction, live fibrosis, and cirrhosis. BA has no known medical
      treatments. The only proven treatment is a surgical portoenterostomy (the Kasai procedure, or
      KP) which can achieve bile drainage and improve outcomes in some cases. The KPs success is
      variable depending on several factors including age of the infant, experience of the surgeon,
      and extent of liver fibrosis at the time of KP.

      In this study, the investigators conduct a phase II trial of a potential new medical therapy
      for BA: pentoxifylline (PTX). PTX is a methylxanthine derivative closely related to caffeine
      that has been used safely in infants with other diseases such as sepsis. In adults, PTX has
      been shown to have a number of properties beneficial to the liver, including preventing liver
      fibrosis, improving liver regeneration, and reducing cirrhosis-related complications.

      The trial's objective is to determine whether PTX has sufficient biological activity against
      BA to warrant further study. PTX will be administered orally for 90 days as an adjunct to
      standard therapy (i.e. KP if appropriate). The primary outcome will measure the change in
      serum conjugated bilirubin levels after 90 days. Secondary outcomes include changes in body
      weight, serum markers, liver imaging, and time to liver transplant in infants with BA.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2013</start_date>
  <completion_date type="Anticipated">January 2019</completion_date>
  <primary_completion_date type="Anticipated">January 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in serum conjugated bilirubin</measure>
    <time_frame>Baseline and after 90 days of therapy</time_frame>
    <description>The investigators will track the change in serum conjugated bilirubin over the course of therapy in patients receiving 90 days of PTX</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Weight</measure>
    <time_frame>Baseline and after 90 days of therapy</time_frame>
    <description>The investigators will track the change in weight over the course of therapy in patients receiving 90 days of PTX</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in serum markers</measure>
    <time_frame>Baseline and up to two years after therapy finishes</time_frame>
    <description>The investigators will track the change in serum liver markers and platelets over the course of two years in patients receiving 90 days of PTX therapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in liver imaging</measure>
    <time_frame>Baseline and up to two years after therapy finishes</time_frame>
    <description>The investigators will track liver ultrasound changes, including liver and spleen size.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to liver transplant</measure>
    <time_frame>Baseline and up to two years after therapy finishes</time_frame>
    <description>The investigators will track time to liver transplant.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Biliary Atresia</condition>
  <arm_group>
    <arm_group_label>Pentoxifylline</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All newly-diagnosed biliary atresia patients fulfilling the study's inclusion criteria will receive oral pentoxifylline, 20 mg/kg/day divided in three doses for a total of 90 days.
The hospital pharmacy will create a 20 mg/ml oral pentoxifylline solution using 400 mg pentoxifylline tablets and established compounding recipes.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pentoxifylline</intervention_name>
    <description>20 mg/kg/day divided in 3 doses, given orally for 90 days</description>
    <arm_group_label>Pentoxifylline</arm_group_label>
    <other_name>Trental</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  0-180 days old

          -  Diagnosed with biliary atresia through liver biopsy and/or intra-operative
             cholangiogram

          -  No previous Kasai portoenterostomy performed at another institution

          -  Able to take medications orally

          -  Legal guardian signs consent after understanding risks and investigational nature of
             study

        Exclusion Criteria:

          -  Infants greater than 180 days old

          -  Infants receiving a Kasai portoenterostomy at another institution

          -  Infants unable to take medications orally
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>180 Days</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sanjiv Harpavat, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Baylor College of Medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ross Shepherd, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Baylor College of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sanjiv Harpavat, MD PhD</last_name>
    <phone>832-824-2099</phone>
    <phone_ext>2144</phone_ext>
    <email>harpavat@bcm.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ross Shepherd, MD</last_name>
    <phone>832-824-2099</phone>
    <phone_ext>1223</phone_ext>
    <email>Ross.Shepherd@bcm.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Texas Children's Hospital and Baylor College of Medicine</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sanjiv Harpavat, MD PhD</last_name>
      <phone>832-824-2099</phone>
      <phone_ext>2144</phone_ext>
      <email>harpavat@bcm.edu</email>
    </contact>
    <contact_backup>
      <last_name>Ross Shepherd, MD</last_name>
      <phone>832-824-2099</phone>
      <phone_ext>1223</phone_ext>
      <email>Ross.Shepherd@bcm.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Sanjiv Harpavat, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ross Shepherd, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mary Brandt, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Shelly Kim, PharmD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Charles Minard, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Paula Hertel, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Milton Finegold, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Perlmutter DH, Shepherd RW. Extrahepatic biliary atresia: a disease or a phenotype? Hepatology. 2002 Jun;35(6):1297-304. Review.</citation>
    <PMID>12029613</PMID>
  </reference>
  <reference>
    <citation>Sokol RJ, Shepherd RW, Superina R, Bezerra JA, Robuck P, Hoofnagle JH. Screening and outcomes in biliary atresia: summary of a National Institutes of Health workshop. Hepatology. 2007 Aug;46(2):566-81. Review.</citation>
    <PMID>17661405</PMID>
  </reference>
  <reference>
    <citation>Garcia AV, Cowles RA, Kato T, Hardy MA. Morio Kasai: a remarkable impact beyond the Kasai procedure. J Pediatr Surg. 2012 May;47(5):1023-7. doi: 10.1016/j.jpedsurg.2012.01.065.</citation>
    <PMID>22595595</PMID>
  </reference>
  <reference>
    <citation>Shneider BL, Brown MB, Haber B, Whitington PF, Schwarz K, Squires R, Bezerra J, Shepherd R, Rosenthal P, Hoofnagle JH, Sokol RJ; Biliary Atresia Research Consortium. A multicenter study of the outcome of biliary atresia in the United States, 1997 to 2000. J Pediatr. 2006 Apr;148(4):467-474.</citation>
    <PMID>16647406</PMID>
  </reference>
  <reference>
    <citation>Weerasooriya VS, White FV, Shepherd RW. Hepatic fibrosis and survival in biliary atresia. J Pediatr. 2004 Jan;144(1):123-5.</citation>
    <PMID>14722530</PMID>
  </reference>
  <reference>
    <citation>Zhang D, Jiang H, Wang Y, Ma J. Pentoxifylline inhibits hepatic stellate cells proliferation via the Raf/ERK pathway. APMIS. 2012 Jul;120(7):572-81. doi: 10.1111/j.1600-0463.2011.02868.x. Epub 2012 Jan 19.</citation>
    <PMID>22716212</PMID>
  </reference>
  <reference>
    <citation>Andrade Wde C, Tannuri U, da Silva LF, Alves VA. Effects of the administration of pentoxifylline and prednisolone on the evolution of portal fibrogenesis secondary to biliary obstruction-an experimental study in growing animals. J Pediatr Surg. 2009 Nov;44(11):2071-7. doi: 10.1016/j.jpedsurg.2009.05.020.</citation>
    <PMID>19944210</PMID>
  </reference>
  <reference>
    <citation>Zein CO, Yerian LM, Gogate P, Lopez R, Kirwan JP, Feldstein AE, McCullough AJ. Pentoxifylline improves nonalcoholic steatohepatitis: a randomized placebo-controlled trial. Hepatology. 2011 Nov;54(5):1610-9. doi: 10.1002/hep.24544. Epub 2011 Aug 24.</citation>
    <PMID>21748765</PMID>
  </reference>
  <reference>
    <citation>Petrowsky H, Breitenstein S, Slankamenac K, Vetter D, Lehmann K, Heinrich S, DeOliveira ML, Jochum W, Weishaupt D, Frauenfelder T, Graf R, Clavien PA. Effects of pentoxifylline on liver regeneration: a double-blinded, randomized, controlled trial in 101 patients undergoing major liver resection. Ann Surg. 2010 Nov;252(5):813-22. doi: 10.1097/SLA.0b013e3181fcbc5e.</citation>
    <PMID>21037437</PMID>
  </reference>
  <reference>
    <citation>Lebrec D, Thabut D, Oberti F, Perarnau JM, Condat B, Barraud H, Saliba F, Carbonell N, Renard P, Ramond MJ, Moreau R, Poynard T; Pentocir Group. Pentoxifylline does not decrease short-term mortality but does reduce complications in patients with advanced cirrhosis. Gastroenterology. 2010 May;138(5):1755-62. doi: 10.1053/j.gastro.2010.01.040. Epub 2010 Jan 25.</citation>
    <PMID>20102716</PMID>
  </reference>
  <reference>
    <citation>Haque KN, Pammi M. Pentoxifylline for treatment of sepsis and necrotizing enterocolitis in neonates. Cochrane Database Syst Rev. 2011 Oct 5;(10):CD004205. doi: 10.1002/14651858.CD004205.pub2. Review. Update in: Cochrane Database Syst Rev. 2015;3:CD004205.</citation>
    <PMID>21975745</PMID>
  </reference>
  <reference>
    <citation>Superina R, Magee JC, Brandt ML, Healey PJ, Tiao G, Ryckman F, Karrer FM, Iyer K, Fecteau A, West K, Burns RC, Flake A, Lee H, Lowell JA, Dillon P, Colombani P, Ricketts R, Li Y, Moore J, Wang KS; Childhood Liver Disease Research and Education Network. The anatomic pattern of biliary atresia identified at time of Kasai hepatoportoenterostomy and early postoperative clearance of jaundice are significant predictors of transplant-free survival. Ann Surg. 2011 Oct;254(4):577-85. doi: 10.1097/SLA.0b013e3182300950.</citation>
    <PMID>21869674</PMID>
  </reference>
  <reference>
    <citation>Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin Trials. 1989 Mar;10(1):1-10.</citation>
    <PMID>2702835</PMID>
  </reference>
  <reference>
    <citation>Best BM, Burns JC, DeVincenzo J, Phelps SJ, Blumer JL, Wilson JT, Capparelli EV, Connor JD; Pediatric Pharmacology Research Unit Network. Pharmacokinetic and tolerability assessment of a pediatric oral formulation of pentoxifylline in kawasaki disease. Curr Ther Res Clin Exp. 2003 Feb;64(2):96-115. doi: 10.1016/S0011-393X(03)00018-3.</citation>
    <PMID>24944359</PMID>
  </reference>
  <reference>
    <citation>Davenport M, Caponcelli E, Livesey E, Hadzic N, Howard E. Surgical outcome in biliary atresia: etiology affects the influence of age at surgery. Ann Surg. 2008 Apr;247(4):694-8. doi: 10.1097/SLA.0b013e3181638627.</citation>
    <PMID>18362634</PMID>
  </reference>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 22, 2013</study_first_submitted>
  <study_first_submitted_qc>January 22, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 24, 2013</study_first_posted>
  <last_update_submitted>September 12, 2017</last_update_submitted>
  <last_update_submitted_qc>September 12, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 14, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Baylor College of Medicine</investigator_affiliation>
    <investigator_full_name>Sanjiv Harpavat</investigator_full_name>
    <investigator_title>Assistant Professor, Department of Pediatrics, Division of Gastroenterology, Hepatology, and Nutrition</investigator_title>
  </responsible_party>
  <keyword>Biliary Atresia</keyword>
  <keyword>Pentoxifylline</keyword>
  <keyword>Trental</keyword>
  <keyword>Serum bilirubin</keyword>
  <keyword>Conjugated bilirubin</keyword>
  <keyword>Liver transplantation</keyword>
  <keyword>Fibrosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Biliary Atresia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pentoxifylline</mesh_term>
    <mesh_term>Bilirubin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>The data for subjects will be shared in aggregate.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

